BioCryst Pharma (BCRX) Misses Q1 EPS by 303c ; Offers Guidance
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.14 +1.67%
Revenue Growth %: +13.7%
Financial Fact:
Loss on foreign currency derivative: -931K
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +13.7%
Financial Fact:
Loss on foreign currency derivative: -931K
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q1 EPS of ($2.98), $3.03 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $156.41 million versus the consensus estimate of $151.66 million.
GUIDANCE:
BioCryst Pharma sees FY2026 revenue of $635-660 million, versus the consensus of $650.2 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
- BuzzFeed sells shares to Byron Allen affiliate for $5.8 million
- Lockheed Martin wins $83 million Army missile contract
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
